Acta medica Indonesiana · 2026
Diagnostic Performance of Non-Invasive Tests in Assessing Liver Fibrosis Among Type 2 Diabetes Mellitus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mufida Annisa Zahra, Hidayat Amal Arifi, Alfaray Ricky Indra, Kholili Ulfa, Wibisono Sony, Sugihartono Titong, Mudjari Nurike Setiyari, Adiwinoto Robert Dwitama, Kurniawati Febri, Miftahussurur Muhammad
Аннотация
BACKGROUND: Noninvasive tools for assessing liver fibrosis are essential, especially in patients with Type 2 Diabetes Mellitus (T2DM) who are at high risk of developing metabolic dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the correlation between the diagnostic accuracy of the Fibrosis-4 Index (FIB-4), aminotransferase-to-platelet ratio index (APRI), and NAFLD fibrosis score (NFS) and the diagnostic accuracy of FibroScan® in Indonesian patients with T2DM.
METHODS: This cross-sectional study enrolled 80 outpatients with T2DM. Liver fibrosis was evaluated using FibroScan®. FIB-4, APRI, and NFS were calculated using routine clinical and laboratory parameters. Correlations between noninvasive scores and liver stiffness measurement (LSM) were analyzed. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance for significant fibrosis (≥F2) and cirrhosis (F3-F4).
RESULTS: MAFLD was present in 67.5% of subjects; significant fibrosis and cirrhosis were found in 25% and 7.5% of subjects, respectively. FIB-4 and NFS showed significant correlations with LSM (ρ = 0.291 and 0.296; p < 0.01), whereas APRI did not. FIB-4, APRI, and NFS demonstrated fair to good diagnostic performance for significant fibrosis (area under the curve (AUC) 0.693, 0.685, 0.693) and excellent performance for cirrhosis (AUC 0.825, 0.860, 0.870). Female sex and HOMA-IR were independent predictors of significant fibrosis; AST and platelet count were predictive of cirrhosis.
CONCLUSION: FIB-4, APRI, and NFS are effective and affordable screening tools for initial fibrosis in patients with T2DM, particularly in low-resource settings. The combination of these measures may enhance the detection of at-risk individuals for referral and further management.
METHODS: This cross-sectional study enrolled 80 outpatients with T2DM. Liver fibrosis was evaluated using FibroScan®. FIB-4, APRI, and NFS were calculated using routine clinical and laboratory parameters. Correlations between noninvasive scores and liver stiffness measurement (LSM) were analyzed. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance for significant fibrosis (≥F2) and cirrhosis (F3-F4).
RESULTS: MAFLD was present in 67.5% of subjects; significant fibrosis and cirrhosis were found in 25% and 7.5% of subjects, respectively. FIB-4 and NFS showed significant correlations with LSM (ρ = 0.291 and 0.296; p < 0.01), whereas APRI did not. FIB-4, APRI, and NFS demonstrated fair to good diagnostic performance for significant fibrosis (area under the curve (AUC) 0.693, 0.685, 0.693) and excellent performance for cirrhosis (AUC 0.825, 0.860, 0.870). Female sex and HOMA-IR were independent predictors of significant fibrosis; AST and platelet count were predictive of cirrhosis.
CONCLUSION: FIB-4, APRI, and NFS are effective and affordable screening tools for initial fibrosis in patients with T2DM, particularly in low-resource settings. The combination of these measures may enhance the detection of at-risk individuals for referral and further management.